Chronic myelomonocytic leukemia with ring sideroblasts/

CMML CMML-RS/SF3B1 MDS-RS/SF3B1 mutational profile phenotype prognosis

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2024
Historique:
received: 14 02 2024
accepted: 08 04 2024
medline: 16 7 2024
pubmed: 16 7 2024
entrez: 16 7 2024
Statut: epublish

Résumé

Chronic myelomonocytic leukemia (CMML) and myelodysplastic syndromes (MDS) with ring sideroblasts (RS) or We compared CMML with and without RS/ A total of 815 patients were included (CMML, n=319, CMML-RS/ CMML-RS/

Identifiants

DOI: 10.3389/fonc.2024.1385987 PMID: 39011475 PMC: PMC11246989
pubmed: 39011475
doi: 10.3389/fonc.2024.1385987
pmc: PMC11246989
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1385987

Informations de copyright

Copyright © 2024 Xicoy, Pomares, Morgades, Germing, Arnan, Tormo, Palomo, Orna, Della Porta, Schulz, Díaz-Beya, Esteban, Molero, Lanino, Avendaño, Hernández, Roldan, Ubezio, Pineda, Díez-Campelo and Zamora.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Blanca Xicoy (B)

Hematology Department, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona; Myeloid Neoplasms Group, Josep Carreras Leukemia Research Institute-Hospital Germans Trias i Pujol, Badalona, Spain.

Helena Pomares (H)

Hematology Department. Institut Català d'Oncologia, Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.

Mireia Morgades (M)

Hematology Department, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona; Myeloid Neoplasms Group, Josep Carreras Leukemia Research Institute-Hospital Germans Trias i Pujol, Badalona, Spain.

Ulrich Germing (U)

Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine Universitätsklinikum, Düsseldorf, Germany.

Montserrat Arnan (M)

Hematology Department. Institut Català d'Oncologia, Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.

Mar Tormo (M)

Hematology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.

Laura Palomo (L)

Hematology Department, Hospital Universitari Vall d'Hebró, Barcelona, Spain.

Elisa Orna (E)

Hematology Department, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona; Myeloid Neoplasms Group, Josep Carreras Leukemia Research Institute-Hospital Germans Trias i Pujol, Badalona, Spain.

Matteo Della Porta (M)

Hematology Department, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Felicitas Schulz (F)

Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine Universitätsklinikum, Düsseldorf, Germany.

Marina Díaz-Beya (M)

Hematology Department, Hospital Clínic, Barcelona, Spain.

Ada Esteban (A)

Hematology Department, Hospital de San Pedro, Logroño, Spain.

Antonieta Molero (A)

Hematology Department, Hospital Universitari Vall d'Hebró, Barcelona, Spain.

Luca Lanino (L)

Hematology Department, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Alejandro Avendaño (A)

Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain.

Francisca Hernández (F)

Hematology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain.

Verónica Roldan (V)

Hematology Department, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain.

Marta Ubezio (M)

Hematology Department, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Alberto Pineda (A)

Hematology Department, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona; Myeloid Neoplasms Group, Josep Carreras Leukemia Research Institute-Hospital Germans Trias i Pujol, Badalona, Spain.

María Díez-Campelo (M)

Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain.

Lurdes Zamora (L)

Hematology Department, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona; Myeloid Neoplasms Group, Josep Carreras Leukemia Research Institute-Hospital Germans Trias i Pujol, Badalona, Spain.

Classifications MeSH